ArticlePloS one2026
The emergence of NDM-1, IMP-7, IMP-26, IMP-62, IMP-76, VIM-4 and VIM-5 producing Pseudomonas aeruginosa strains, identification of a novel sequence type (ST3891) and analysis of virulence genes from a Malaysian tertiary hospital.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Pseudomonas aeruginosa is a medically crucial nosocomial pathogen causing significant mortality in patients with weakened immune systems. It is sensitive to carbapenems such as meropenem and imipenem. However, recent research indicates the rise and rapid transmission of carbapenem-resistant P. aeruginosa (CRPA). This study analysed the phenotypic and genotypic traits linked with CRPA strains obtained from the University Malaya Medical Centre (UMMC), a Malaysian tertiary teaching hospital. MDR P. aeruginosa (n = 215) were isolated from the Medical Microbiology Diagnostic Laboratory (MMDL). The VITEK-2 automated system was used for antimicrobial susceptibility and data for susceptibility to various antimicrobial agents were retrieved from the MMDL database at the UMMC. The minimum inhibitory concentration (MIC) of the carbapenems (meropenem and imipenem) was analysed using the broth microdilution method. Pyocyanin, protease and biofilm assays were conducted to assess the phenotypic traits. Furthermore, polymerase chain reaction (PCR) was used to detect six virulence genes and three carbapenemase genes. P. aeruginosa strains that displayed high-level resistance to meropenem and imipenem showed an association with 140 strains (65.1%) that were strong biofilm producers (OD570nm ≥ 3.0). The majority of the strains (73.5%) exhibited high to moderate pyocyanin production, while 95.3% were capable of secreting protease. Among the six virulence genes tested, most of the strains harboured the toxR (109/215, 50.7%) and algD (108/215, 50.2%) genes. The identification of carbapenem genes showed blaIMP (n = 24, 11.2%) followed by blaNDM (n = 16, 7.4%) and blaVIM (n = 4, 1.86%). A novel sequence type, ST3891 was discovered using multilocus sequence typing (MLST). The rising incidence of carbapenem-resistant strains is concerning, as carbapenems with antipseudomonal activity play a vital role in treating P. aeruginosa infections. Additionally, this study found a positive correlation between increased biofilm production and resistance to carbapenem in P. aeruginosa. This emphasises the importance of stringent infection control strategies, particularly considering the clonal dissemination of the high-risk ST235 clone and the identification of the novel ST3891 strain in Malaysia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.